Harshavardhan Krishna
Internal Medicine · Hamtramck, MINPI 1154354769
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $997 and has fallen 98.2% since, to $18 in 2025.
Across 148 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$486
- AbbVie$387
- Ironwood Pharmaceuticals, Inc$277
- Johnson & Johnson$261
- Lilly USA, LLC$207
- Alkermes, Inc.$183
- plus $984 from 18 others
Across 64 payments — averaging $2553.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$45K
- Astrazeneca UK Limited$38K
- Abbott$30K
- AbbVie$20K
- Takeda Pharmaceuticals U.S.A., Inc.$16K
- AstraZeneca$15K
- plus $258 from 1 others
What the payments were for
- Food & beverage$2,786100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $486 |
| AbbVie(2 entities) | 24 | $387 |
| Ironwood Pharmaceuticals, Inc | 17 | $277 |
| Johnson & Johnson | 5 | $261 |
| Lilly USA, LLC | 15 | $207 |
| Alkermes, Inc. | 4 | $183 |
| Cardiovascular Systems Inc. | 1 | $150 |
| Pfizer | 6 | $125 |
| GSK | 8 | $125 |
| Boehringer Ingelheim | 5 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $92 |
| Novo Nordisk | 4 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Amgen | 2 | $41 |
| Dexcom, Inc. | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Gilead | 2 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $22 |
| Lundbeck LLC | 1 | $21 |
| Orexo US, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Alk-abello, Inc | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,786 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Hamtramck
- Terry SmithAnn Arbor$2.3M
- Michael ValituttoKalamazoo$1.8M
- Ulka VaishampayanAnn Arbor$996K
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
- A FendrickAnn Arbor$347K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.